Repligen Co. (NASDAQ:RGEN) Director Karen A. Dawes sold 274 shares of Repligen stock in a transaction on Tuesday, September 14th. The shares were sold at an average price of $294.26, for a total value of $80,627.24. Following the transaction, the director now owns 93,908 shares in the company, valued at approximately $27,633,368.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Karen A. Dawes also recently made the following trade(s):
- On Tuesday, August 17th, Karen A. Dawes sold 17,514 shares of Repligen stock. The shares were sold at an average price of $253.77, for a total transaction of $4,444,527.78.
NASDAQ RGEN opened at $299.88 on Friday. The stock has a market capitalization of $16.46 billion, a PE ratio of 167.53 and a beta of 0.90. The company has a 50 day moving average price of $250.87 and a two-hundred day moving average price of $214.31. Repligen Co. has a 12-month low of $138.00 and a 12-month high of $300.09.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC raised its holdings in Repligen by 1.4% during the second quarter. Parametric Portfolio Associates LLC now owns 128,246 shares of the biotechnology company’s stock valued at $25,600,000 after buying an additional 1,799 shares in the last quarter. Comerica Bank raised its holdings in Repligen by 2.5% during the second quarter. Comerica Bank now owns 102,773 shares of the biotechnology company’s stock valued at $26,676,000 after buying an additional 2,509 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in Repligen by 1.4% during the second quarter. Thrivent Financial for Lutherans now owns 113,290 shares of the biotechnology company’s stock valued at $22,615,000 after purchasing an additional 1,618 shares during the last quarter. Walleye Capital LLC acquired a new position in Repligen during the second quarter valued at approximately $212,000. Finally, Zacks Investment Management grew its holdings in Repligen by 34.9% during the second quarter. Zacks Investment Management now owns 17,446 shares of the biotechnology company’s stock valued at $3,482,000 after purchasing an additional 4,511 shares during the last quarter. Institutional investors own 83.82% of the company’s stock.
Several research firms have recently commented on RGEN. Craig Hallum boosted their price target on shares of Repligen from $251.00 to $258.00 and gave the company a “buy” rating in a report on Wednesday, July 28th. Stephens boosted their target price on Repligen from $255.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 20th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $247.60.
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.